Posted by Michael Wonder on 24 Jan 2025
Clarity receives US FDA fast track designation for Cu 64 SAR-bisPSMA in biochemical recurrence of prostate cancer
24 January 2025 - Clarity Pharmaceuticals is pleased to announce that the US FDA has granted fast track designation for 64Cu-SAR-bisPSMA for positron emission tomography imaging of prostate-specific membrane antigen positive prostate cancer lesions in patients with biochemical recurrence of prostate cancer following definitive therapy.
This milestone builds on Clarity's earlier receipt of fast track designation for 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy.
